Findings hold promise for developing regenerative therapies for spinal cord injuries and diseases such as multiple sclerosis
Stem cell technology has long offered the hope of regenerating tissue to repair broken or damaged neural tissue. Findings from a team of UC Davis investigators have brought this dream a step closer by developing a method to generate functioning brain cells that produce myelin — a fatty, insulating sheath essential to normal neural conduction.
“Our findings represent an important conceptual advance in stem cell research,” said Wenbin Deng, principal investigator of the study and associate professor at the UC Davis Department of Biochemistry and Molecular Medicine. “We have bioengineered the first generation of myelin-producing cells with superior regenerative capacity.”
The brain is made up predominantly of two cell types: neurons and glial cells. Neurons are regarded as responsible for thought and sensation. Glial cells surround, support and communicate with neurons, helping neurons process and transmit information using electrical and chemical signals. One type of glial cell — the oligodendrocyte — produces a sheath called myelin that provides support and insulation to neurons. Myelin, which has been compared to insulation around electrical wires that helps to prevent short circuits, is essential for normal neural conduction and brain function; well-recognized conditions involving defective myelin development or myelin loss include multiple sclerosis and leukodystrophies.
In this study, the UC Davis team first developed a novel protocol to efficiently induce embryonic stem cells (ESCs) to differentiate into oligodendroglial progenitor cells (OPCs), early cells that normally develop into oligodendrocytes. Although this has been successfully done by other researchers, the UC Davis method results in a purer population of OPCs, according to Deng, with fewer other cell types arising from their technique.
They next compared electrophysiological properties of the derived OPCs to naturally occurring OPCs. They found that unlike natural OPCs, the ESC-derived OPCs lacked sodium ion channels in their cell membranes, making them unable to generate spikes when electrically stimulated. Using a technique called viral transduction, they then introduced DNA that codes for sodium channels into the ESC-derived OPCs. These OPCs then expressed ion channels in their cells and developed the ability to generate spikes.
According to Deng, this is the first time that scientists have successfully generated OPCs with so-called spiking properties. This achievement allowed them to compare the capabilities of spiking cells to non-spiking cells.
In cell culture, they found that only spiking OPCs received electrical input from neurons, and they showed superior capability to mature into oligodendrocytes.
They also transplanted spiking and non-spiking OPCs into the spinal cord and brains of mice that are genetically unable to produce myelin. Both types of OPCs had the capability to mature into oligo-dendrocytes and produce myelin, but those from spiking OPCs produced longer and thicker myelin sheaths around axons.
“We actually developed ‘super cells’ with an even greater capacity to spike than natural cells,” Deng said. “This appears to give them an edge for maturing into oligodendrocytes and producing better myelin.”
It is well known that adult human neural tissue has a poor capacity to regenerate naturally. Although early cells such as OPCs are present, they do not regenerate tissue very effectively when disease or injury strikes.
Deng believes that replacing glial cells with the enhanced spiking OPCs to treat neural injuries and diseases has the potential to be a better strategy than replacing neurons, which tend to be more problematic to work with. Providing the proper structure and environment for neurons to live may be the best approach to regenerate healthy neural tissue. He also notes that many diverse conditions that have not traditionally been considered to be myelin-related diseases – including schizophrenia, epilepsy and amyotrophic lateral sclerosis (ALS) – actually are now recognized to involve defective myelin.
The Latest on: Stem cell technology
New study: Stem cell manufacturing market worth 14.61 billion USD by 2023
on March 16, 2018 at 2:10 pm
The major players in the Stem Cell Manufacturing Market include Thermo Fisher Scientific (US), Merck Group (Germany), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Miltenyi Biotec (Germany), Takara Bio Group (Japan), STEMCELL Technologies ... […]
Natcore Streamlines Process For High-Efficiency, Silver-Less Solar Cells
on March 16, 2018 at 8:56 am
Natcore Technology Inc., a company focused on significantly lowering the costs and improving the power output of solar cells, says it has dramatically streamlined the fabrication method for its Natcore Foil Cell, allowing for even lower-cost production ... […]
Theralase Technologies : Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells
on March 15, 2018 at 4:06 am
Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ... […]
Turbocharging fuel cells with a multifunctional nanotechnology catalyst
on March 14, 2018 at 4:18 pm
but the researchers worked to improve solid oxide fuel cells, which are found in some prototypical fuel cell cars. The research insights could also aid in honing supercapacitors and technology paired with solar panels, thus advancing sustainable energy bey ... […]
Q&A: JinkoSolar discusses half cut cells, multi-busbars and bifacial technology
on March 14, 2018 at 6:57 am
pv magazine: By cutting cells in half and arranging them in a module in a standard formation, JinkoSolar’s new HC Series panels can increase power output by 5-10 W at little extra cost. Sounds simple, but is it? Can you explain how such a power boost is ... […]
Global Stem Cell Technologies and Applications Market 2018-2018 - Visiongain Report
on March 13, 2018 at 7:09 am
The global stem cell technologies and applications market is estimated to have reached $12,040 million and is expected to grow at a CAGR of 13.2% in the first half of the forecast period. The market is expected to grow at a CAGR of 11.5% from 2017 to 2028. […]
Novel technology for anticancer drug delivery on demand
on March 9, 2018 at 10:50 am
The research team applied this technology to deliver the chemotherapeutic drug Doxorubicin to cervical cancer cells (HeLa cells) in the laboratory. They observed that the drug was able to exit the vesicles, reach the nucleus of the cancer cells ... […]
Global Stem Cell Partnering Report 2018: Access to Deals and Agreements by the World's Leading Healthcare Companies Since 2012
on March 9, 2018 at 9:39 am
The "Global Stem Cell Partnering 2012-2018 ... deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include ... […]
via Google News and Bing News